Tekla Life Sciences Investors Paid Distribution
29 Settembre 2023 - 4:35PM
Business Wire
On September 29, 2023, Tekla Life Sciences Investors paid a
distribution of $0.32 per share. It is currently estimated that
this distribution is derived from net realized long-term capital
gains. The composition of this and subsequent distributions may
vary from quarter to quarter because it may be materially impacted
by future realized gains and losses on securities. The aggregate of
the net unrealized appreciation of portfolio securities and net
realized gains on sale of securities is $44,305,054, of which
$10,004,278 represents net unrealized appreciation of portfolio
securities.
The following table sets forth the estimated amounts of the
current distribution, paid on September 29, 2023, and the
cumulative distributions paid this fiscal year-to-date from the
following sources: net investment income, net realized short-term
capital gains, net realized long-term capital gains and return of
capital or other capital source. The Fund estimates that it has
distributed more than its income and net realized capital gains;
therefore, a portion of your distribution may be a return of
capital. A return of capital may occur, for example, when some or
all the money that you have invested in the Fund is paid back to
you. A return of capital distribution does not necessarily reflect
the Fund’s investment performance and should not be confused with
‘yield’ or ‘income’. All amounts are expressed per common
share.
Current Distribution
Percentage Breakdown of
Current Distribution
Total Cumulative Distributions
for the Fiscal Year to Date1
Percentage Breakdown of the
Total Cumulative Distributions for the Fiscal Year to Date1
Net Investment Income
$0.0000
0%
$0.0000
0%
Net Realized ST Cap Gains
$0.0000
0%
$0.0000
0%
Net Realized LT Cap Gains
$0.3200
100%
$0.3200
25%
Return of Capital or Other Capital
Source
$0.0000
0%
$0.9600
75%
TOTAL (per common share):
$0.3200
100%
$1.2800
100%
The table below includes information relating to the Fund’s
performance based on its NAV for certain periods.
Average annual return at NAV for the
period from July 31, 2018 through July 31, 2023
3.74%
Annualized current distribution rate
expressed as percentage of NAV as of July 31, 2023
8.10%
Cumulative total return at NAV for the
fiscal year through July 31, 20232
9.18%
Cumulative fiscal year-to-date
distribution rate expressed as a percentage of NAV as of July 31,
20231
8.10%
You should not draw any conclusions about the Fund’s investment
performance from the amount of this distribution or from the terms
of the Fund’s managed distribution policy.
The amounts and sources of distributions reported in this press
release are only estimates and are not being provided for tax
reporting purposes. The actual amounts and sources of the amounts
for tax reporting purposes will depend upon the Fund’s investment
experience during the remainder of its fiscal year and may be
subject to changes based on tax regulations. The Fund will send you
a Form 1099-DIV for the calendar year that will tell you how to
report these distributions for federal income tax purposes.
Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund
that invests in companies in the healthcare industry.
Tekla Capital Management LLC, the Fund’s investment adviser, is
a Boston, MA based healthcare-focused investment manager with
approximately $3.1 billion of net assets under management as of
June 30, 2023. Tekla also serves as investment adviser to Tekla
Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities
Fund (NYSE: THQ) and Tekla World Healthcare Fund (NYSE: THW),
closed-end funds that invest in companies in the healthcare and
life sciences industries. Information regarding the Funds and Tekla
Capital Management LLC can be found at www.teklacap.com.
Please contact Destra Capital Advisors, the Fund’s marketing and
investor support services agent, at HQL@destracapital.com or call
(877) 855-3434 if you have any questions regarding HQL.
1 The Fund’s current fiscal year began on
October 1, 2022.
2 Cumulative total return at NAV is the
percentage change in the Fund’s NAV and includes all distributions
and assumes the reinvestment of those distributions for the period
of September 30, 2022 through July 31, 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230929847449/en/
Destra Capital Advisors HQL@destracapital.com (877) 855-3434
Grafico Azioni abrdn Life Sciences Inve... (NYSE:HQL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni abrdn Life Sciences Inve... (NYSE:HQL)
Storico
Da Dic 2023 a Dic 2024